Redeye’s first comments on CellaVision’s report for Q1’21. The report showed stronger sales than we expected at SEK 134m vs. our SEK 123m, a flat development compared to last year. The gross margin was also higher at 69% compared with the 67% expected. Organic sales were a strong 7% driven by a very strong development in EMEA, while the other regions continue to be weak. Encouraging comments about returning to a gradual recovery of the markets, and we like that the gross margin was back at pre-pandemic high levels. The long-term prospects are still excellent, and we are likely to make some upward adjustments to our estimates.